S&P 500   5,009.00 (-0.26%)
DOW   37,762.47 (+0.02%)
QQQ   424.07 (-0.42%)
AAPL   167.18 (-0.49%)
MSFT   404.76 (-1.72%)
META   503.07 (+1.80%)
GOOGL   156.34 (+0.56%)
AMZN   179.53 (-0.97%)
TSLA   150.26 (-3.34%)
NVDA   849.38 (+1.07%)
AMD   154.91 (+0.58%)
NIO   4.01 (+2.56%)
BABA   68.98 (+0.23%)
T   16.28 (+0.99%)
F   12.03 (-0.08%)
MU   112.72 (-3.10%)
GE   154.05 (-1.04%)
CGC   7.78 (+19.88%)
DIS   112.83 (-0.10%)
AMC   2.93 (-1.68%)
PFE   25.37 (-0.20%)
PYPL   62.11 (-1.82%)
XOM   118.50 (-0.11%)
S&P 500   5,009.00 (-0.26%)
DOW   37,762.47 (+0.02%)
QQQ   424.07 (-0.42%)
AAPL   167.18 (-0.49%)
MSFT   404.76 (-1.72%)
META   503.07 (+1.80%)
GOOGL   156.34 (+0.56%)
AMZN   179.53 (-0.97%)
TSLA   150.26 (-3.34%)
NVDA   849.38 (+1.07%)
AMD   154.91 (+0.58%)
NIO   4.01 (+2.56%)
BABA   68.98 (+0.23%)
T   16.28 (+0.99%)
F   12.03 (-0.08%)
MU   112.72 (-3.10%)
GE   154.05 (-1.04%)
CGC   7.78 (+19.88%)
DIS   112.83 (-0.10%)
AMC   2.93 (-1.68%)
PFE   25.37 (-0.20%)
PYPL   62.11 (-1.82%)
XOM   118.50 (-0.11%)
S&P 500   5,009.00 (-0.26%)
DOW   37,762.47 (+0.02%)
QQQ   424.07 (-0.42%)
AAPL   167.18 (-0.49%)
MSFT   404.76 (-1.72%)
META   503.07 (+1.80%)
GOOGL   156.34 (+0.56%)
AMZN   179.53 (-0.97%)
TSLA   150.26 (-3.34%)
NVDA   849.38 (+1.07%)
AMD   154.91 (+0.58%)
NIO   4.01 (+2.56%)
BABA   68.98 (+0.23%)
T   16.28 (+0.99%)
F   12.03 (-0.08%)
MU   112.72 (-3.10%)
GE   154.05 (-1.04%)
CGC   7.78 (+19.88%)
DIS   112.83 (-0.10%)
AMC   2.93 (-1.68%)
PFE   25.37 (-0.20%)
PYPL   62.11 (-1.82%)
XOM   118.50 (-0.11%)
S&P 500   5,009.00 (-0.26%)
DOW   37,762.47 (+0.02%)
QQQ   424.07 (-0.42%)
AAPL   167.18 (-0.49%)
MSFT   404.76 (-1.72%)
META   503.07 (+1.80%)
GOOGL   156.34 (+0.56%)
AMZN   179.53 (-0.97%)
TSLA   150.26 (-3.34%)
NVDA   849.38 (+1.07%)
AMD   154.91 (+0.58%)
NIO   4.01 (+2.56%)
BABA   68.98 (+0.23%)
T   16.28 (+0.99%)
F   12.03 (-0.08%)
MU   112.72 (-3.10%)
GE   154.05 (-1.04%)
CGC   7.78 (+19.88%)
DIS   112.83 (-0.10%)
AMC   2.93 (-1.68%)
PFE   25.37 (-0.20%)
PYPL   62.11 (-1.82%)
XOM   118.50 (-0.11%)
NASDAQ:BEAT

BioTelemetry (BEAT) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$1.70
$2.25
50-Day Range
$71.46
$72.27
52-Week Range
$27.35
$73.10
Volume
273,012 shs
Average Volume
83,490 shs
Market Capitalization
$56.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.78

BioTelemetry MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
213.7% Upside
$6.78 Price Target
Short Interest
Healthy
0.82% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.69 out of 5 stars

Medical Sector

844th out of 914 stocks

Surgical & Medical Instruments Industry

85th out of 94 stocks

BEAT stock logo

About BioTelemetry Stock (NASDAQ:BEAT)

BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.

BEAT Stock News Headlines

Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
BEAT Stock Earnings: HeartBeam Meets EPS for Q4 2023
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
HeartBeam Inc BEAT
Why BioTelemetry (BEAT) Is Soaring Today
See More Headlines
Receive BEAT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioTelemetry and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
4/18/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:BEAT
Fax
N/A
Employees
1,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.78
High Stock Price Target
$8.00
Low Stock Price Target
$5.55
Potential Upside/Downside
+213.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-14,640,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.61 per share

Miscellaneous

Free Float
24,402,000
Market Cap
$56.87 million
Optionable
Not Optionable
Beta
-1.22
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Joseph H. Capper (Age 57)
    CEO, Pres & Director
    Comp: $1.21M
  • Ms. Heather C. Getz (Age 46)
    Exec. VP, CFO & Chief Admin. Officer
    Comp: $616.68k
  • Mr. Fred Broadway III (Age 51)
    Pres of BioTel Heart
    Comp: $524.63k
  • Mr. Daniel M. Wisniewski (Age 57)
    Sr. VP of Technical Operations
    Comp: $506.54k
  • Dr. Andrei G. Stoica
    Chief Technology Officer
  • Cody Cowper
    VP of Legal & Corp. Sec.
  • Amy M. Knapp
    Vice president of Corp. Communications
  • Mr. Tim Raher
    Sr. VP of HR
  • Dr. Peter R. Kowey
    Medical Director and Chairman of Medical Advisory Board
  • Mr. Scott Satin
    Pres & GM of BioTel Research

BEAT Stock Analysis - Frequently Asked Questions

Should I buy or sell BioTelemetry stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BioTelemetry in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BEAT shares.
View BEAT analyst ratings
or view top-rated stocks.

What is BioTelemetry's stock price target for 2024?

1 brokers have issued twelve-month price objectives for BioTelemetry's stock. Their BEAT share price targets range from $5.55 to $8.00. On average, they expect the company's stock price to reach $6.78 in the next twelve months. This suggests a possible upside of 213.7% from the stock's current price.
View analysts price targets for BEAT
or view top-rated stocks among Wall Street analysts.

Are investors shorting BioTelemetry?

BioTelemetry saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 159,400 shares, an increase of 20.7% from the March 15th total of 132,100 shares. Based on an average daily trading volume, of 133,400 shares, the days-to-cover ratio is currently 1.2 days. Approximately 0.8% of the shares of the stock are short sold.
View BioTelemetry's Short Interest
.

When is BioTelemetry's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our BEAT earnings forecast
.

How were BioTelemetry's earnings last quarter?

BioTelemetry, Inc. (NASDAQ:BEAT) posted its quarterly earnings data on Wednesday, March, 20th. The medical research company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. During the same quarter last year, the company earned ($0.45) EPS.

What is Joseph H. (Joe) Capper's approval rating as BioTelemetry's CEO?

40 employees have rated BioTelemetry Chief Executive Officer Joseph H. (Joe) Capper on Glassdoor.com. Joseph H. (Joe) Capper has an approval rating of 53% among the company's employees. This puts Joseph H. (Joe) Capper in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of BioTelemetry own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioTelemetry investors own include NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), AT&T (T), AbbVie (ABBV), Alibaba Group (BABA), Netflix (NFLX) and Gilead Sciences (GILD).

When did BioTelemetry IPO?

BioTelemetry (BEAT) raised $16 million in an IPO on Thursday, November 11th 2021. The company issued 2,750,000 shares at $5.50-$6.50 per share.

This page (NASDAQ:BEAT) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners